These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28247415)

  • 21. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.
    Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W
    Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
    Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
    Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer.
    Hapuarachchige S; Huang CT; Donnelly MC; Bařinka C; Lupold SE; Pomper MG; Artemov D
    Mol Pharm; 2020 Jan; 17(1):98-108. PubMed ID: 31840521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
    Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.
    Moffett S; Mélançon D; DeCrescenzo G; St-Pierre C; Deschénes F; Saragovi HU; Gold P; Cuello AC
    Hybridoma (Larchmt); 2007 Dec; 26(6):363-72. PubMed ID: 18158780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
    Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
    Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
    Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
    Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA.
    Psimadas D; Valotassiou V; Alexiou S; Tsougos I; Georgoulias P
    Cancer Invest; 2018 Feb; 36(2):118-128. PubMed ID: 29393702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
    Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
    J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
    Chang SS; Reuter VE; Heston WD; Gaudin PB
    Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591.
    Parker SA; Diaz IL; Anderson KA; Batt CA
    Protein Expr Purif; 2013 Jun; 89(2):136-45. PubMed ID: 23500147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
    Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
    Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
    Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
    Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
    Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
    Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
    [No Abstract]   [Full Text] [Related]  

  • 39. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
    Vallabhajosula S; Nikolopoulou A; Jhanwar YS; Kaur G; Tagawa ST; Nanus DM; Bander NH; Goldsmith SJ
    Curr Radiopharm; 2016; 9(1):44-53. PubMed ID: 25771365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
    Gong MC; Chang SS; Sadelain M; Bander NH; Heston WD
    Cancer Metastasis Rev; 1999; 18(4):483-90. PubMed ID: 10855791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.